Panel 6

Vaccines

Melinda M. Pettigrew, Mark R. Alderson, Lauren O. Bakaletz, Stephen J. Barenkamp, Anders P. Hakansson, Kevin M. Mason, Johanna Nokso-Koivisto, Janak Patel, Stephen I. Pelton, Timothy F. Murphy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To review the literature on progress regarding (1) effectiveness of vaccines for prevention of otitis media (OM) and (2) development of vaccine antigens for OM bacterial and viral pathogens. Data Sources: PubMed database of the National Library of Science. Review Methods: We performed literature searches in PubMed for OM pathogens and candidate vaccine antigens, and we restricted the searches to articles in English that were published between July 2011 and June 2015. Panel members reviewed literature in their area of expertise. Conclusions: Pneumococcal conjugate vaccines (PCVs) are somewhat effective for the prevention of pneumococcal OM, recurrent OM, OM visits, and tympanostomy tube insertions. Widespread use of PCVs has been associated with shifts in pneumococcal serotypes and bacterial pathogens associated with OM, diminishing PCV effectiveness against AOM. The 10-valent pneumococcal vaccine containing Haemophilus influenzae protein D (PHiD-CV) is effective for pneumococcal OM, but results from studies describing the potential impact on OM due to H influenzae have been inconsistent. Progress in vaccine development for H influenzae, Moraxella catarrhalis, and OM-associated respiratory viruses has been limited. Additional research is needed to extend vaccine protection to additional pneumococcal serotypes and other otopathogens. There are likely to be licensure challenges for protein-based vaccines, and data on correlates of protection for OM vaccine antigens are urgently needed. Implications for Practice: OM continues to be a significant health care burden globally. Prevention is preferable to treatment, and vaccine development remains an important goal. As a polymicrobial disease, OM poses significant but not insurmountable challenges for vaccine development.

Original languageEnglish (US)
Pages (from-to)S76-S87
JournalOtolaryngology - Head and Neck Surgery (United States)
Volume156
Issue number4_suppl
DOIs
StatePublished - Apr 1 2017

Fingerprint

Otitis Media
Vaccines
Conjugate Vaccines
Pneumococcal Vaccines
Antigens
PubMed
Human Influenza
Library Science
Middle Ear Ventilation
Satellite Viruses
Moraxella (Branhamella) catarrhalis
Information Storage and Retrieval
Licensure
Databases

Keywords

  • children
  • Haemophilus influenzae
  • Moraxella catarrhalis
  • otitis media
  • Streptococcus pneumoniae
  • vaccines

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

Pettigrew, M. M., Alderson, M. R., Bakaletz, L. O., Barenkamp, S. J., Hakansson, A. P., Mason, K. M., ... Murphy, T. F. (2017). Panel 6: Vaccines. Otolaryngology - Head and Neck Surgery (United States), 156(4_suppl), S76-S87. https://doi.org/10.1177/0194599816632178

Panel 6 : Vaccines. / Pettigrew, Melinda M.; Alderson, Mark R.; Bakaletz, Lauren O.; Barenkamp, Stephen J.; Hakansson, Anders P.; Mason, Kevin M.; Nokso-Koivisto, Johanna; Patel, Janak; Pelton, Stephen I.; Murphy, Timothy F.

In: Otolaryngology - Head and Neck Surgery (United States), Vol. 156, No. 4_suppl, 01.04.2017, p. S76-S87.

Research output: Contribution to journalArticle

Pettigrew, MM, Alderson, MR, Bakaletz, LO, Barenkamp, SJ, Hakansson, AP, Mason, KM, Nokso-Koivisto, J, Patel, J, Pelton, SI & Murphy, TF 2017, 'Panel 6: Vaccines', Otolaryngology - Head and Neck Surgery (United States), vol. 156, no. 4_suppl, pp. S76-S87. https://doi.org/10.1177/0194599816632178
Pettigrew MM, Alderson MR, Bakaletz LO, Barenkamp SJ, Hakansson AP, Mason KM et al. Panel 6: Vaccines. Otolaryngology - Head and Neck Surgery (United States). 2017 Apr 1;156(4_suppl):S76-S87. https://doi.org/10.1177/0194599816632178
Pettigrew, Melinda M. ; Alderson, Mark R. ; Bakaletz, Lauren O. ; Barenkamp, Stephen J. ; Hakansson, Anders P. ; Mason, Kevin M. ; Nokso-Koivisto, Johanna ; Patel, Janak ; Pelton, Stephen I. ; Murphy, Timothy F. / Panel 6 : Vaccines. In: Otolaryngology - Head and Neck Surgery (United States). 2017 ; Vol. 156, No. 4_suppl. pp. S76-S87.
@article{9c696ca3d4124ed5afa2042d05c90865,
title = "Panel 6: Vaccines",
abstract = "Objective: To review the literature on progress regarding (1) effectiveness of vaccines for prevention of otitis media (OM) and (2) development of vaccine antigens for OM bacterial and viral pathogens. Data Sources: PubMed database of the National Library of Science. Review Methods: We performed literature searches in PubMed for OM pathogens and candidate vaccine antigens, and we restricted the searches to articles in English that were published between July 2011 and June 2015. Panel members reviewed literature in their area of expertise. Conclusions: Pneumococcal conjugate vaccines (PCVs) are somewhat effective for the prevention of pneumococcal OM, recurrent OM, OM visits, and tympanostomy tube insertions. Widespread use of PCVs has been associated with shifts in pneumococcal serotypes and bacterial pathogens associated with OM, diminishing PCV effectiveness against AOM. The 10-valent pneumococcal vaccine containing Haemophilus influenzae protein D (PHiD-CV) is effective for pneumococcal OM, but results from studies describing the potential impact on OM due to H influenzae have been inconsistent. Progress in vaccine development for H influenzae, Moraxella catarrhalis, and OM-associated respiratory viruses has been limited. Additional research is needed to extend vaccine protection to additional pneumococcal serotypes and other otopathogens. There are likely to be licensure challenges for protein-based vaccines, and data on correlates of protection for OM vaccine antigens are urgently needed. Implications for Practice: OM continues to be a significant health care burden globally. Prevention is preferable to treatment, and vaccine development remains an important goal. As a polymicrobial disease, OM poses significant but not insurmountable challenges for vaccine development.",
keywords = "children, Haemophilus influenzae, Moraxella catarrhalis, otitis media, Streptococcus pneumoniae, vaccines",
author = "Pettigrew, {Melinda M.} and Alderson, {Mark R.} and Bakaletz, {Lauren O.} and Barenkamp, {Stephen J.} and Hakansson, {Anders P.} and Mason, {Kevin M.} and Johanna Nokso-Koivisto and Janak Patel and Pelton, {Stephen I.} and Murphy, {Timothy F.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1177/0194599816632178",
language = "English (US)",
volume = "156",
pages = "S76--S87",
journal = "Otolaryngology - Head and Neck Surgery (United States)",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "4_suppl",

}

TY - JOUR

T1 - Panel 6

T2 - Vaccines

AU - Pettigrew, Melinda M.

AU - Alderson, Mark R.

AU - Bakaletz, Lauren O.

AU - Barenkamp, Stephen J.

AU - Hakansson, Anders P.

AU - Mason, Kevin M.

AU - Nokso-Koivisto, Johanna

AU - Patel, Janak

AU - Pelton, Stephen I.

AU - Murphy, Timothy F.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Objective: To review the literature on progress regarding (1) effectiveness of vaccines for prevention of otitis media (OM) and (2) development of vaccine antigens for OM bacterial and viral pathogens. Data Sources: PubMed database of the National Library of Science. Review Methods: We performed literature searches in PubMed for OM pathogens and candidate vaccine antigens, and we restricted the searches to articles in English that were published between July 2011 and June 2015. Panel members reviewed literature in their area of expertise. Conclusions: Pneumococcal conjugate vaccines (PCVs) are somewhat effective for the prevention of pneumococcal OM, recurrent OM, OM visits, and tympanostomy tube insertions. Widespread use of PCVs has been associated with shifts in pneumococcal serotypes and bacterial pathogens associated with OM, diminishing PCV effectiveness against AOM. The 10-valent pneumococcal vaccine containing Haemophilus influenzae protein D (PHiD-CV) is effective for pneumococcal OM, but results from studies describing the potential impact on OM due to H influenzae have been inconsistent. Progress in vaccine development for H influenzae, Moraxella catarrhalis, and OM-associated respiratory viruses has been limited. Additional research is needed to extend vaccine protection to additional pneumococcal serotypes and other otopathogens. There are likely to be licensure challenges for protein-based vaccines, and data on correlates of protection for OM vaccine antigens are urgently needed. Implications for Practice: OM continues to be a significant health care burden globally. Prevention is preferable to treatment, and vaccine development remains an important goal. As a polymicrobial disease, OM poses significant but not insurmountable challenges for vaccine development.

AB - Objective: To review the literature on progress regarding (1) effectiveness of vaccines for prevention of otitis media (OM) and (2) development of vaccine antigens for OM bacterial and viral pathogens. Data Sources: PubMed database of the National Library of Science. Review Methods: We performed literature searches in PubMed for OM pathogens and candidate vaccine antigens, and we restricted the searches to articles in English that were published between July 2011 and June 2015. Panel members reviewed literature in their area of expertise. Conclusions: Pneumococcal conjugate vaccines (PCVs) are somewhat effective for the prevention of pneumococcal OM, recurrent OM, OM visits, and tympanostomy tube insertions. Widespread use of PCVs has been associated with shifts in pneumococcal serotypes and bacterial pathogens associated with OM, diminishing PCV effectiveness against AOM. The 10-valent pneumococcal vaccine containing Haemophilus influenzae protein D (PHiD-CV) is effective for pneumococcal OM, but results from studies describing the potential impact on OM due to H influenzae have been inconsistent. Progress in vaccine development for H influenzae, Moraxella catarrhalis, and OM-associated respiratory viruses has been limited. Additional research is needed to extend vaccine protection to additional pneumococcal serotypes and other otopathogens. There are likely to be licensure challenges for protein-based vaccines, and data on correlates of protection for OM vaccine antigens are urgently needed. Implications for Practice: OM continues to be a significant health care burden globally. Prevention is preferable to treatment, and vaccine development remains an important goal. As a polymicrobial disease, OM poses significant but not insurmountable challenges for vaccine development.

KW - children

KW - Haemophilus influenzae

KW - Moraxella catarrhalis

KW - otitis media

KW - Streptococcus pneumoniae

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=85018964771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018964771&partnerID=8YFLogxK

U2 - 10.1177/0194599816632178

DO - 10.1177/0194599816632178

M3 - Article

VL - 156

SP - S76-S87

JO - Otolaryngology - Head and Neck Surgery (United States)

JF - Otolaryngology - Head and Neck Surgery (United States)

SN - 0194-5998

IS - 4_suppl

ER -